

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
23 March 2023 (23.03.2023)



(10) International Publication Number
WO 2023/043923 A1

(51) International Patent Classification:

A61K 31/425 (2006.01) *A61P 35/00* (2006.01)
A61K 31/5415 (2006.01) *C07D 417/06* (2006.01)
A61K 31/554 (2006.01) *C07D 513/04* (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

(21) International Application Number:

PCT/US2022/043660

Published:

— with international search report (Art. 21(3))

(22) International Filing Date:

15 September 2022 (15.09.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/245,718 17 September 2021 (17.09.2021) US

(71) Applicant: **BOUNDLESS BIO, INC.** [US/US]; 9880
Campus Point Drive, Suite 120, San Diego, California
92121 (US).

(72) Inventors: **PINKERTON, Anthony B.**; 9880 Campus
Point Drive, Suite 120, San Diego, California 92121 (US).
MAUGER, Jacques; 9880 Campus Point Drive, Suite 120,
San Diego, California 92121 (US). **TRUONG, Yen Pham
Hong**; 9880 Campus Point Drive, Suite 120, San Diego,
California 92121 (US). **ELSDON, Rachelle Janette**; 9880
Campus Point Drive, Suite 120, San Diego, California
92121 (US). **MEYER, Stephen Todd**; 9880 Campus Point
Drive, Suite 120, San Diego, California 92121 (US).

(74) Agent: **BONNEFOUS, Celine**; WILSON SONSINI
GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto,
California 94304 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF

(57) Abstract: Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a cyclic sulfonamide RNR inhibitor disclosed herein.



WO 2023/043923 A1